95 related articles for article (PubMed ID: 21865017)
1. Solid lipid nanoparticles comprising internal Compritol 888 ATO, tripalmitin and cacao butter for encapsulating and releasing stavudine, delavirdine and saquinavir.
Kuo YC; Chung CY
Colloids Surf B Biointerfaces; 2011 Dec; 88(2):682-90. PubMed ID: 21865017
[TBL] [Abstract][Full Text] [Related]
2. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles.
Kuo YC; Su FL
Int J Pharm; 2007 Aug; 340(1-2):143-52. PubMed ID: 17418986
[TBL] [Abstract][Full Text] [Related]
3. Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles.
Kuo YC; Chen HH
Int J Pharm; 2009 Jan; 365(1-2):206-13. PubMed ID: 18848610
[TBL] [Abstract][Full Text] [Related]
4. Methylmethacrylate-sulfopropylmethacrylate nanoparticles with surface RMP-7 for targeting delivery of antiretroviral drugs across the blood-brain barrier.
Kuo YC; Lee CL
Colloids Surf B Biointerfaces; 2012 Feb; 90():75-82. PubMed ID: 22024400
[TBL] [Abstract][Full Text] [Related]
5. Cationic solid lipid nanoparticles with primary and quaternary amines for release of saquinavir and biocompatibility with endothelia.
Kuo YC; Wang CC
Colloids Surf B Biointerfaces; 2013 Jan; 101():101-5. PubMed ID: 22796778
[TBL] [Abstract][Full Text] [Related]
6. Effect of electromagnetic field and surface modification on the electrical behavior of novel solid lipid nanoparticles covered with l-arginine.
Kuo YC; Lin CW
Colloids Surf B Biointerfaces; 2009 Jun; 71(1):45-51. PubMed ID: 19181492
[TBL] [Abstract][Full Text] [Related]
7. Cationic solid lipid nanoparticles with cholesterol-mediated surface layer for transporting saquinavir to the brain.
Kuo YC; Wang CC
Biotechnol Prog; 2014; 30(1):198-206. PubMed ID: 24167123
[TBL] [Abstract][Full Text] [Related]
8. Targeting delivery of saquinavir to the brain using 83-14 monoclonal antibody-grafted solid lipid nanoparticles.
Kuo YC; Ko HF
Biomaterials; 2013 Jul; 34(20):4818-30. PubMed ID: 23545288
[TBL] [Abstract][Full Text] [Related]
9. Solid lipid nanoparticles and nanosuspension formulation of Saquinavir: preparation, characterization, pharmacokinetics and biodistribution studies.
Dodiya SS; Chavhan SS; Sawant KK; Korde AG
J Microencapsul; 2011; 28(6):515-27. PubMed ID: 21728760
[TBL] [Abstract][Full Text] [Related]
10. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery.
Paliwal R; Rai S; Vaidya B; Khatri K; Goyal AK; Mishra N; Mehta A; Vyas SP
Nanomedicine; 2009 Jun; 5(2):184-91. PubMed ID: 19095502
[TBL] [Abstract][Full Text] [Related]
11. Polyethyleneimine/poly-(γ-glutamic acid)/poly(lactide-co-glycolide) nanoparticles for loading and releasing antiretroviral drug.
Kuo YC; Yu HW
Colloids Surf B Biointerfaces; 2011 Nov; 88(1):158-64. PubMed ID: 21764569
[TBL] [Abstract][Full Text] [Related]
12. Transport of saquinavir across human brain-microvascular endothelial cells by poly(lactide-co-glycolide) nanoparticles with surface poly-(γ-glutamic acid).
Kuo YC; Yu HW
Int J Pharm; 2011 Sep; 416(1):365-75. PubMed ID: 21736932
[TBL] [Abstract][Full Text] [Related]
13. Electromagnetic interference in the permeability of saquinavir across the blood-brain barrier using nanoparticulate carriers.
Kuo YC; Kuo CY
Int J Pharm; 2008 Mar; 351(1-2):271-81. PubMed ID: 17976933
[TBL] [Abstract][Full Text] [Related]
14. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables.
Das S; Ng WK; Kanaujia P; Kim S; Tan RB
Colloids Surf B Biointerfaces; 2011 Nov; 88(1):483-9. PubMed ID: 21831615
[TBL] [Abstract][Full Text] [Related]
15. Physicochemical properties of nevirapine-loaded solid lipid nanoparticles and nanostructured lipid carriers.
Kuo YC; Chung JF
Colloids Surf B Biointerfaces; 2011 Apr; 83(2):299-306. PubMed ID: 21194902
[TBL] [Abstract][Full Text] [Related]
16. Characterization and formulation optimization of solid lipid nanoparticles in vitamin K1 delivery.
Liu CH; Wu CT; Fang JY
Drug Dev Ind Pharm; 2010 Jul; 36(7):751-61. PubMed ID: 20136495
[TBL] [Abstract][Full Text] [Related]
17. Preparation and characterization of ibuprofen solid lipid nanoparticles with enhanced solubility.
Potta SG; Minemi S; Nukala RK; Peinado C; Lamprou DA; Urquhart A; Douroumis D
J Microencapsul; 2011; 28(1):74-81. PubMed ID: 21171818
[TBL] [Abstract][Full Text] [Related]
18. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug.
Jain A; Agarwal A; Majumder S; Lariya N; Khaya A; Agrawal H; Majumdar S; Agrawal GP
J Control Release; 2010 Dec; 148(3):359-67. PubMed ID: 20854859
[TBL] [Abstract][Full Text] [Related]
19. The role of daidzein-loaded sterically stabilized solid lipid nanoparticles in therapy for cardio-cerebrovascular diseases.
Gao Y; Gu W; Chen L; Xu Z; Li Y
Biomaterials; 2008 Oct; 29(30):4129-36. PubMed ID: 18667234
[TBL] [Abstract][Full Text] [Related]
20. Oral solid compritol 888 ATO nanosuspension of simvastatin: optimization and biodistribution studies.
Shah M; Chuttani K; Mishra AK; Pathak K
Drug Dev Ind Pharm; 2011 May; 37(5):526-37. PubMed ID: 21128704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
